Vanda Q2 2026 net loss $62.5M ($1.04/share); Fanapt sales up 23% to $36M; reiterates FY revenue guidance $240-290M

Vanda Pharmaceuticals Inc.

Net loss $62.5M ($1.04 diluted EPS) in Q2 2026 vs net loss $27.2M ($0.46) in Q2 2025; operating loss $62.4M.
Fanapt net product sales $36.0M (+23% YoY); total prescriptions up 31% YoY.
Total net product sales $50.5M (-4% YoY); HETLIOZ sales $5.6M (-66% YoY) due to $7M shipment shift to Q3.
Cash $170.0M as of June 30, 2026, down $32.3M in Q2; expects to fund operations through end of 2027.
FY 2026 total revenue guidance reiterated at $240-290M; BYSANTI launch H2 2026; Quimilza PDUFA Dec 12, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.